Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AdvisorShares Psychedelics ETF (NY:PSIL)

20.75 +1.98 (+10.58%)
Streaming Delayed Price Updated: 3:24 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AdvisorShares Psychedelics ETF

< Previous 1 2 3 4 5 Next >
News headline image
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
News headline image
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Up In December; Down YTD ↗
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. 
Via Talk Markets
News headline image
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Declined 1.6% This Week ↗
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD. 
Via Talk Markets
Topics ETFs
News headline image
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
News headline image
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week ↗
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week. 
Via Talk Markets
News headline image
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
News headline image
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan 
Via Benzinga
Topics Cannabis
News headline image
GH Research Drags Down Psychedelic Drug Stocks Index By 7% ↗
The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. 
Via Talk Markets
News headline image
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? 
Via Benzinga
Topics Initial Public Offering
News headline image
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court 
Via Benzinga
Topics Economy
News headline image
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
Via Benzinga
Topics Intellectual Property
News headline image
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts 
Via Benzinga
News headline image
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution 
Via Benzinga
News headline image
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares 
Via Benzinga
News headline image
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
News headline image
September Summary: Largest Psychedelic Drug Stocks Dropped 14% ↗
Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining... 
Via Talk Markets
News headline image
EXCLUSIVE: What's Next For Cannabis? Industry Experts Discuss Game-Changing New Policies ↗
Cannabis reform has moved one step closer to reality at the federal level on Wednesday, with the Senate Banking Committee approving the Secure and Fair Enforcement Regulation (SAFER) Banking Act. 
Via Benzinga
Topics Cannabis
News headline image
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
News headline image
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and... 
Via Talk Markets
News headline image
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
News headline image
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... 
Via Talk Markets
News headline image
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
Via Talk Markets
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
News headline image
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
News headline image
The 7 ETFs In The Fringe Portfolio Were, On Average, Up Last Week ↗
If you are interested in any of the cannabis, psychedelic, Bitcoin, AI, 
Via Talk Markets
Topics Artificial Intelligence Cannabis ETFs
News headline image
The Portfolio Of 7 "Fringe" ETFs Is Down 9% MTD; Still Up YTD ↗
Analysis of the cannabis, psychedelic, bitcoin, artificial intelligence, 
Via Talk Markets
Topics Artificial Intelligence Cannabis ETFs
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.